"168 Body mass index does not influence the efficacy of abatacept in patients with psoriatic arthritis: results from the ASTRAEA trial" by Iain McInnes

Article

168 Body mass index does not influence the efficacy of abatacept in patients with psoriatic arthritis: results from the ASTRAEA trial

Rheumatology (2018)

Iain McInnes, University of Glasgow
Gianfranco Ferraccioli, Catholic University of the Sacred Heart
Maria-Antonietta D’Agostino, University of Paris
Manuela Le Bars, Bristol-Myers Squibb
Subhashis Banerjee, Bristol-Myers Squibb
Harris A Ahmad, Bristol-Myers Squibb
Yedid Elbez
June Ye, Bristol-Myers Squibb
Philip Mease, University of Washington

Link

Disciplines

Physical Therapy,
Medicine and Health Sciences and
Endocrinology, Diabetes, and Metabolism

Publication Date

April 1, 2018

DOI

10.1093/rheumatology/key075.392

Citation Information

Iain McInnes, Gianfranco Ferraccioli, Maria-Antonietta D’Agostino, Manuela Le Bars, et al.. "168 Body mass index does not influence the efficacy of abatacept in patients with psoriatic arthritis: results from the ASTRAEA trial" Rheumatology Vol. 57 (2018)
Available at: http://works.bepress.com/philip-mease/11/